Microba Launches Next Generation Healthcare Testing
28.2.2023 12:44:00 EET | Business Wire | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005713/en/
MetaXplore™ GI Plus can help you explore the impact your patients’ gut microbiome may be having on their health. MetaXplore™ GI Plus translates diagnostic gastrointestinal markers and targeted pathogen, protist and parasite panels1 alongside metagenomic-driven gut microbiome insights2 for over 28,000* microbial species and their function. (Photo: Business Wire)
Microba’s Chief Executive Officer, Dr Luke Reid said, “The new MetaXplore™ test range delivers an important advancement in how microbiome test information can be applied in a healthcare setting. We continue to make progress at the forefront of this field to advance the application of microbiome testing in a healthcare setting towards a future where it can be routine in health and disease management, much like a blood test is today.”
The new MetaXplore™ range provides diagnostic gastrointestinal health testing together with metagenomic-driven gut microbiome analysis to deliver comprehensive gastrointestinal testing solutions for Healthcare Professionals. The MetaXplore™ test range has been developed together with healthcare professionals and brought to market under a new brand called Co-Biome™.
The range consists of 3 products: MetaXplore™, MetaXplore™ GI and MetaXplore™ GI Plus. Key features include:
- Easy to interpret report format designed specifically for healthcare professionals to support efficient patient consultation
- Scientifically graded clinical insights using National Health and Medical Research Council guidelines
- Diagnostic and investigative gastrointestinal health markers (faecal calprotectin, faecal occult blood, lactoferrin, pancreatic elastase, secretory IgA, Zonulin, Fecal pH)
- Diagnostic pathogen and parasite detection (E.coli pathotypes, C.difficile pathotypes, Campylobacter spp., Yersinia enterocolitica, Vibrio spp., Aeromonas spp., Salmonella spp., Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp., Dientamoeba fragilis, Cyclospora cayetanensis.)
- Complete microbiome profiling (Microbial diversity, richness and profiling of over 28,000+ microbial species including bacteria, fungi, parasite and archaea detection, together with parasite detection of Blastocystis subtypes 1-9 and other eukaryotes)
- Microbiome production and consumption of metabolites (Butyrate, acetate, propionate, 3-indolepropionic acid (IPA), hexa-acylated, lipopolysaccharides (hexa-LPS), trimethylamine (TMA), hydrogen sulphide, branched-chain amino acids (BCAA), B.fragilis toxin, methane, beta-glucuronidase, Mucin, oxalate)
A core component of Microba’s strategy is to leverage the Company’s world-leading technology and capability to advance the clinical application of microbiome testing to become embedded as a routine part of health and disease management. The MetaXplore™ test range through Co-Biome™ represents an important step forward in that strategy by breaking new ground in the application of microbiome testing in healthcare.
Microba’s Chief Scientific Officer, Assoc Prof. Lutz Krause said, “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting. This test range is expected to significantly expand the total addressable market for Microba’s testing products.”
The test range through Co-Biome™ can be accessed in Australia through a healthcare professional, and following the launch, it is expected to then be rolled out through Microba’s growing international distribution partner network.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005713/en/
Contact information
Simon Hinsley simon@nwrcommunications.com.au
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 16:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom